Application and Generalization of Flutter Mucus Clearance Device

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00816881

Enrollment

356

Registered

2009-01-05

Start date

2009-01-31

Completion date

2010-03-31

Last updated

2012-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Pulmonary Disease, Chronic Obstructive, flutter, airway clearance, sputum, Physical Therapy Techniques

Brief summary

The purpose of this study is to evaluate the clinical outcome and safety of flutter mucus clearance devices.

Detailed description

Respiratory diseases are still increasing in elder population. Sputum detaining is a common contributing factor to acute exacerbation. The fluttering mucus clearance technique is expected to be a physical assisting therapy enhancing airway secretion clearance but need more clinical randomized control trial evidence.

Interventions

DEVICEflutter mucus clearance device

five minutes every session, four sessions per day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

40 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Pulmonary department: available to perform the device, in-hospital patients * Male and female * Age: 45 - 85 years * Chronic bronchitis, COPD * Thoracic surgery department and surgical department (upper abdomen): * Patients with endotracheal intubation of general anesthesia * Age: 40-75 years

Exclusion criteria

* Not available to perform the procedure * Untreated pneumothorax * Diffusion interstitial lung disease * Acute coronary syndrome * Third stage hypertension * Advanced cancer * Severe heart, liver, renal , blood system and endocrine system dysfunction * Noninvasive mechanical ventilation more than 6 hrs per day * Patients with invasive ventilation and cannot weaning and extubation within 48 hours * Active hemoptysis

Design outcomes

Primary

Measure	Time frame
days of fever (body temperature reach 38 degree Celsius or higher), days of antibiotics therapy, hospital length of stay, or at 28 days	one year

Secondary

Measure	Time frame
rate of noninvasive mechanical ventilation, rate of trachea intubation, mortality due to any reason until discharge, total fees of in-hospital	one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026